Biocellvia co-signed a scientific article on a NASH breakthrough innovation with Prof. Diehl from Duke University

Scientific publication with Prof. Leclercq
Biocellvia co-signs with Prof. Leclercq a scientific article about its own technology dedicated to NAFLD/NASH
septembre 26, 2019
Optimization of bleomycin concentration in IPF rodent model
Optimization of bleomycin concentration in IPF rodent model
octobre 1, 2019
Show all

Biocellvia co-signed a scientific article on a NASH breakthrough innovation with Prof. Diehl from Duke University

Scientific publication with Prof. Diehl

Prof. Yvon Julé, Biocellvia’s Chief Scientific Officer, just co-signed a key publication on NASH disease with Dr. Saurabh Chatterjee (University of South Carolina) and Prof. Anna-Mae Diehl (Duke University). This scientific article entitled “Exogenous PP2A inhibitor exacerbates the progression of nonalcoholic fatty liver disease via NOX2-dependent activation of miR21” has been published in American Journal of Physiology. This publication highlights the role of a key mechanism in NASH disease : “The present report tests the hypothesis that an exogenous PP2A inhibitor leads to hepatic inflammation and fibrogenesis via an NADPH oxidase 2 (NOX2)-dependent pathway in NAFLD. Results showed that microcystin (MC) administration, a potent PP2A inhibitor found in environmental exposure, led to an exacerbation of NAFLD pathology with increased CD68immunoreactivity, the release of proinflammatory cytokines, and stellate cell activation, a process that was attenuated in mice that lacked the p47phox gene and miR21 knockout mice.”

Major breakthrough thanks to Biocellvia

Biocellvia played a key role in this major breakthrough : the french company performed fully-automated and quantitative digital image analysis on mice liver sections for this scientific study. Accuracy and reliability of Biocellvia’s technology enabled to observe precisely the mechanism described in the article. Biocellvia is a french startup that has created a digital and fully-automated image analysis technology that enables to evaluate the efficacy of lead molecules at preclinical stage. Biocellvia has commercialized its own software dedicated to NAFLD/NASH to pharmaceutical industry as a service. Actually, biotechs, CRO and Big Pharma send to Biocellvia blocks, unstained slides, stained slides or digital scans and Biocellvia performs (histology and) digital image analysis to evaluate the level of severity of the disease and so the level of efficacy of molecules. A full study is performed in a couple of days only. Biocellvia’s clients pay the service with a defined price per image, so they only pay what they need.

Scientific partners like Duke University (Prof. Diehl)

Next to this commercial activity, Biocellvia keeps on taking parts to research on NAFLD and NASH. Biocellvia helps academic researchers by providing to them its fully-automated and digital image analysis technology. Biocellvia has already built strong partnerships with worldwide research teams (mainly Europe & North America) such as University of Louvain, Duke University and University of South Carolina for NASH.

Link to the article :

I have a background as a researcher academic with more than 30 years of age experience. Professor at the "Mayo Clinic " (USA), I created the company Biocellvia in 2011 with my son Olivier Julé. During the creation of the box, I perceived the power of digital image analysis in the framework of the research, and the interest that they cause.

Laisser un commentaire

Votre adresse de messagerie ne sera pas publiée. Les champs obligatoires sont indiqués avec *

We are working hard on our new website!
Unfortunately, we haven't yet found a technology as fast as Biocellvia's .
Please be kind to our old design and come say hello to the new one when it is up and running.